Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia

被引:6
|
作者
Moradi, Arman [1 ]
Maleki, Majid [2 ]
Ghaemmaghami, Zahra [2 ]
Khajali, Zahra [2 ]
Noohi, Feridoun [2 ]
Moghadam, Maryam Hosseini [2 ]
Kalyinia, Samira [2 ]
Mowla, Seyed Javad [1 ]
Seidah, Nabil G. [3 ]
Malakootian, Mahshid [2 ]
机构
[1] Tarbiat Modares Univ, Fac Biol Sci, Dept Mol Genet, Tehran, Iran
[2] Iran Univ Med Sci, Cardiogenet Res Ctr, Rajaie Cardiovasc Med & Res Ctr, Tehran, Iran
[3] Univ Montreal, Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ, Canada
基金
美国国家科学基金会;
关键词
pre-mature CAD; Familial Hypercholesterolemia; loss-of-function; LDLR; PCSK9 (proprotein convertase subtilisin kexin type 9); RECEPTOR GENE; LIPOPROTEIN; BINDING; CLINICIAN; GUIDANCE; DATABASE; DOMAIN; RISK; FH;
D O I
10.3389/fgene.2021.625959
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Familial hypercholesterolemia (FH) is a common, yet underdiagnosed, genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol levels, which can increase the risk of early-onset coronary artery disease (CAD). In the present study, we screened the nucleotide variations of the LDLR and PCSK9 genes, as well as a part of the APOB gene, in Iranian patients with FH and premature CAD to find the genetic cause of the disorder. Fifteen unrelated individuals with a clinical diagnosis of FH and premature CAD were recruited. Direct DNA sequencing was applied to screen the whole coding exons and exon-intron boundaries of the LDLR and PCSK9 genes and the main parts of their introns, together with exon 26 of the APOB gene. The pathogenicity of the identified mutations was investigated via either segregation analyses in the family or in silico predictive software. Six different point mutations (p.Cys148Tyr, p.Cys216Tyr, p.Cys302Trp, p.Cys338Trp, p.Leu479Gln, and p.G593Afs*72) in LDLR and a double mutation (p.Asp172His and p.Ala53Val) in both LDLR and PCSK9 genes were identified in seven families with clinically diagnosed FH (43%), whereas no pathogenic mutations were found in eight families with clinically diagnosed FH. This study is the first to identify 1 pathogenic mutation in the LDLR gene (c.1014C > G [p.Cys338Trp]) and to cosegregate it from the affected individual in the family. No mutations were found in the APOB gene, whereas several silent mutations/polymorphisms were identified in the LDLR and PCSK9 genes. Genetic testing and reports on nucleotide alterations in the Iranian population are still limited. Our findings not only further confirm the significant role of FH in the incidence of premature CAD but also enlarge the spectrum of LDLR and PCSK9 variations and exhibit the heterogeneity of FH in Iranians. In patients with no mutation in the examined genes, the disease could be begotten either by a polygenic cause or by gene defects occurring in other related genes and regions not targeted in this study.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] MUTATIONS IN LDLR, APOB, PCSK9 AND APOE GENES CONTRIBUTE TO THE GENETIC SPECTRUM OF FAMILIAL HYPERCHOLESTEROLAEMIA IN THE NORTH OF ENGLAND
    Johnston, L.
    Potter, A.
    Carey, P.
    Luvai, A.
    McKenna, P.
    Weaver, J.
    Pattman, S.
    Kamaruddin, S.
    Arutchevelam, V.
    Anderson, M.
    Burns, M.
    Hopper, N.
    Sutton, R.
    McAnulty, C.
    Curtis, A.
    Neely, R.
    ATHEROSCLEROSIS, 2018, 275 : E79 - E79
  • [22] COST-EFFECTIVENESS OF CORONARY ARTERY CALCIUM TO GUIDE PCSK9 INHIBITOR THERAPY AMONG PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    Hong, Jonathan
    Bittencourt, Marcio
    Blankstein, Ron
    Shapiro, Michael
    Blaha, Michael
    Cainzos-Achirica, Miguel
    Virani, Salim
    Santos, Raul D.
    Nasir, Khurram
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1973 - 1973
  • [23] PCSK9 AND LDLRAP1 SEQUENCING ANALYSIS IN SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLEMIA AND NEITHER MUTATION IN LDLR NOR APOB GENES
    Civeira, F.
    Tejedor, T.
    Stef, M.
    Palacios, L.
    Mateo-Gallego, R.
    Lamiquiz, I.
    de Castro-Oros, I.
    Cenarro, A.
    ATHEROSCLEROSIS, 2014, 235 (02) : E55 - E55
  • [24] PREVALENCE OF FAMILIAL HYPERCHOLESTEROLEMIA IN PATIENTS WITH PREMATURE CORONARY ARTERY DISEASE IN VIENAM
    Kim, N. T.
    Vu, H. P.
    Nguyen, M. N. T.
    Do, D. L.
    Le, T. T.
    Truong, T. H.
    ATHEROSCLEROSIS, 2020, 315 : E39 - E39
  • [25] PCSK9 analysis in familial hypercholesterolaemia patients negative for LDLR and APOB mutations
    George, P. M.
    Homer, V. M.
    Laurie, A. D.
    Hurndell, N.
    Scott, R. S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 135 - 135
  • [26] A Decision Aid for the Use of PCSK9 Inhibitors in Patients With Familial Hypercholesterolemia
    Farwati, Medhat
    Shaw, Kevin
    Hargraves, Ian G.
    Montori, Victor M.
    Kullo, Iftikhar J.
    CIRCULATION, 2018, 138
  • [27] How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana, Luis
    Plana, Nuria
    Perez-Calahorra, Sofia
    Ibarretxe, Daiana
    Lamiquiz-Moneo, Itziar
    Pedro-Botet, Juan
    Suarez-Tembra, Manuel
    Valdivielso, Pedro
    Ortega, Emilio
    Civeira, Fernando
    ATHEROSCLEROSIS, 2017, 262 : 107 - 112
  • [28] LDLR, PCSK9, AND LDLRAP1 MUTATIONS IN THE SAME PATIENT IN A FAMILIAL HYPERCHOLESTEROLEMIA (FH) FAMILY
    Cocci, Guido
    Cenci, Alessandra
    Bordicchia, Marica
    Sarzani, Riccardo
    ATHEROSCLEROSIS, 2017, 263 : E232 - E232
  • [29] Methylation status of LDLR, PCSK9 and LDLRAP1 is associated with cardiovascular events in familial hypercholesterolemia
    Marcal, Elisangela da Silva Rodrigues
    Borges, Jessica Bassani
    Bastos, Gisele Medeiros
    Hirata, Thiago Dominguez Crespo
    de Oliveira, Victor Fernandes
    Goncalves, Rodrigo Marques
    Faludi, Andre Arpad
    Franca, Joao Italo Dias
    Silva, Daiana Vitor de Oliveira
    Malaquias, Vanessa Barbosa
    Luchessi, Andre Ducati
    Silbiger, Vivian Nogueira
    Nakazone, Marcelo Arruda
    Carmo, Tayanne Silva
    Silva Souza, Doroteia Rossi
    Sampaio, Marcelo Ferraz
    Hirata, Rosario Dominguez Crespo
    Hirata, Mario Hiroyuki
    EPIGENOMICS, 2024, 16 (11-12) : 809 - 820
  • [30] Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis
    Chora, Joana Rita
    Medeiros, Ana Margarida
    Alves, Ana Catarina
    Bourbon, Mafalda
    GENETICS IN MEDICINE, 2018, 20 (06) : 591 - 598